Skip to main content Back to Top
Advertisement

4/3/2020

Octreotide Injection

Products Affected - Description

    • Octreotide Acetate injection, Fresenius Kabi, 100 mcg/mL, 1 mL vial, 10 count, NDC 63323-0376-01
    • Octreotide Acetate injection, Hikma, 100 mcg/mL, 1 mL vial, 10 count, NDC 00641-6175-10
    • Octreotide Acetate injection, Hikma, 50 mcg/mL, 1 mL vial, 10 count, NDC 00641-6174-10
    • Octreotide Acetate injection, Hikma, 500 mcg/mL, 1 mL vial, 10 count, NDC 00641-6176-10
    • Octreotide Acetate injection, Sagent, 100 mcg/mL, 1 mL vial, 10 count, NDC 25021-0452-01
    • Octreotide Acetate injection, Sagent, 1000 mcg/mL, 5 mL vial, 1 count, NDC 25021-0455-05
    • Octreotide Acetate injection, Sagent, 50 mcg/mL, 1 mL vial, 10 count, NDC 25021-0451-01
    • Octreotide Acetate injection, Sagent, 500 mcg/mL, 1 mL vial, 10 count, NDC 25021-0453-01
    • Octreotide Acetate injection, Teva, 100 mcg/mL, 1 mL vial, 25 count, NDC 00703-3311-04
    • Octreotide Acetate injection, Teva, 1000 mcg/mL, 5 mL vial, 1 count, NDC 00703-3343-01
    • Octreotide Acetate injection, Teva, 200 mcg/mL, 5 mL vial, 1 count, NDC 00703-3333-01
    • Octreotide Acetate injection, Teva, 50 mcg/mL, 1 mL vial, 25 count, NDC 00703-3301-04

Reason for the Shortage

    • Fresenius Kabi did not provide a reason for the shortage.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional did not provide a reason for the shortage.
    • Sagent has octreotide on shortage due to manufacturing delay.
    • Sun Pharma is not currently marketing octreotide.
    • Teva did not provide a reason for the shortage.
    • Novartis has Sandostatin available. The 200 mcg/mL 5 mL vials were discontinued in early-2018.

Available Products

    • Sandostatin injection, Novartis, 100 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0181-01
    • Sandostatin injection, Novartis, 50 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0180-01
    • Sandostatin injection, Novartis, 500 mcg/mL, 1 mL ampule, 10 count, NDC 00078-0182-01
    • Octreotide Acetate injection, Fresenius Kabi, 1000 mcg/mL, 5 mL vial, 1 count, NDC 63323-0379-05
    • Octreotide Acetate injection, Fresenius Kabi, 200 mcg/mL, 5 mL vial, 1 count, NDC 63323-0378-05
    • Octreotide Acetate injection, Fresenius Kabi, 50 mcg/mL, 1 mL vial, 10 count, NDC 63323-0365-01
    • Octreotide Acetate injection, Fresenius Kabi, 500 mcg/mL, 1 mL vial, 10 count, NDC 63323-0377-01
    • Octreotide Acetate injection, Hikma, 1,000 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6178-10
    • Octreotide Acetate injection, Hikma, 200 mcg/mL, 5 mL multiple dose vial, 1 count, NDC 00641-6177-10
    • Octreotide Acetate injection, Mylan Institutional, 100 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0245-01
    • Octreotide Acetate injection, Mylan Institutional, 50 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0239-01
    • Octreotide Acetate injection, Mylan Institutional, 500 mcg/mL, 1 mL syringe, 10 count, NDC 67457-0246-01
    • Octreotide Acetate injection, Sagent, 200 mcg/mL, 5 mL vial, 1 count, NDC 25021-0454-05
    • Octreotide Acetate injection, Teva, 500 mcg/mL, 1 mL vial, 25 count, NDC 00703-3321-04

Estimated Resupply Dates

    • Fresenius Kabi has octreotide 100 mcg/mL 1 ml vials on back order and the company estimates a release date in early-April 2020.
    • Hikma has octreotide 100 mcg/mL 1 mL vials and 500 mcg/mL 1 mL vials on back order and the company estimates a release date of early-April 2020. The 50 mcg/mL 1 mL vials are on back order and the company estimates a release date in late-October 2020.
    • Sagent has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, 500 mcg/mL 1 mL vials, and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date of January 2021.
    • Teva has octreotide 50 mcg/mL 1 mL vials, 100 mcg/mL 1 mL vials, 200 mcg/mL 5 mL vials, and 1,000 mcg/mL 5 mL vials on back order and the company estimates a release date in mid-July 2020.

Updated

Updated April 3, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created March 16, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.